Corrects paragraph 3 to say the drug showed reduction of 7.9 mmHg, not 11.7 mmHg, in mid-stage study
March 10 (Reuters) - Mineralys Therapeutics MLYS.O said on Monday its experimental drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending its shares up about 43% before the bell.
In the late-stage study, the treatment called lorundrostat showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg (millimeters of mercury) at week six. The benefit was sustained through week 12, with a further reduction to 11.7 mmHg.
The drug also reduced systolic blood pressure by 7.9 mmHg in a mid-stage trial when compared to a placebo, the company said.
Lorundrostat inhibits the production of aldosterone, a hormone that can contribute to high blood pressure.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。